Inhibitory effects of imatinib on vitamin D₃ synthesis in human keratinocytes.

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the presence of the BCR‑ABL1 fusion gene, a constitutively active, oncogenic tyrosine kinase that is responsible for the clinical features of CML. Tyrosine kinase inhibitors, such as imatinib, have markedly altered the treatment of CML. However, tyrosine kinase inhibitors are… (More)
DOI: 10.3892/mmr.2014.3074